<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792346</url>
  </required_header>
  <id_info>
    <org_study_id>RS618/14(1611)</org_study_id>
    <nct_id>NCT04792346</nct_id>
  </id_info>
  <brief_title>Ten Fraction Adjuvant Hypofractionated Radiotherapy in Node Positive Breast Cancer</brief_title>
  <acronym>HIPOMAMMLINF</acronym>
  <official_title>a Feasibility Study of Accelerated Hypofractionated Radiotherapy in Node Positive Breast Cancer Patients Treated With Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Elena Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Giuseppe Sanguineti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Silvia Takanen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Serena Nucciarelli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Francesco Rulli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maria Papale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Valeria Landoni</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mauro Caterino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diana Giannarelli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ilaria Farina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paola Franzoso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regina Elena Cancer Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-operative loco-regional (LR) hypofractionated radiotherapy (Hypo-RT) is an attractive&#xD;
      approach in locally advanced breast cancer (LABC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present is a single arm phase II study assessing toxicity levels after 34 Gy/10 fxs/2 wks&#xD;
      to the whole breast/chest wall and to the draining lymph nodes; an optional single fraction 8&#xD;
      Gy boost was administered with electrons to the tumor bed in patients who had undergone&#xD;
      conservative surgery. Both acute (CTCAE v4.0) and late (LENT/SOMA) toxicity were collected.&#xD;
      All pts but those who underwent mastectomy without reconstruction or with temporary expander&#xD;
      were also asked to rate their cosmetic outcome according to the Harvard. Toxicity was&#xD;
      assessed weekly during RT and then at each follow-up examination (1, 3, 6 months and then&#xD;
      yearly).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">March 2, 2021</completion_date>
  <primary_completion_date type="Actual">January 7, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>acute toxicity assessment</measure>
    <time_frame>60 months</time_frame>
    <description>rate of acute toxicity according to CTCAE v4.0 scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to evaluate late toxicity</measure>
    <time_frame>60 months</time_frame>
    <description>rate of late to according to soma lent scale</description>
  </secondary_outcome>
  <enrollment type="Actual">61</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>breast/chest wall radiotherapy</intervention_name>
    <description>34 Gy/10 fxs/2 wks to the whole breast/chest wall and locoregional lymph nodes; an optional single fraction 8 Gy boost was administered with electrons to the tumor bed in patients undergoing conservative surgery</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population included breast cancer patients with nodal involvement who underwent&#xD;
        conservative surgery or mastectomy, followed by post operative locoregional radiotherapy&#xD;
        after conservative surgery or mastectomy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients affected by invasive breast cancer who underwent conservative breast surgery&#xD;
             or mastectomy and axillary dissection, followed by post operative radiotherapy at the&#xD;
             level of the breast/chest wall, and of the supraclavicular, third axillary level +/-&#xD;
             internal mammary chain nodes.&#xD;
&#xD;
          -  pT1-3 disease pN1-2, cT1-3 disease if neoadjuvant chemotherapy , cN + cytologically&#xD;
             and/or histologically assessed;&#xD;
&#xD;
          -  ECOG Performance status ≤2;&#xD;
&#xD;
          -  histologically negative surgical margins&#xD;
&#xD;
          -  no distant metastases&#xD;
&#xD;
          -  no prior chest radiotherapy&#xD;
&#xD;
          -  life expectancy ≥ 5 years&#xD;
&#xD;
          -  no prior cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-epithelial breast cancer (sarcoma, lymphoma etc.)&#xD;
&#xD;
          -  Metastases at the level of the internal chain mammary and / or supra-clavicular lymph&#xD;
             nodes histologically assessed&#xD;
&#xD;
          -  pT4 neoplasms or inflammatory breast carcinoma&#xD;
&#xD;
          -  Distant metastasis&#xD;
&#xD;
          -  Concomitant chemotherapy&#xD;
&#xD;
          -  history of prior controlateral breast tumor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Pinnaro</last_name>
    <role>Principal Investigator</role>
    <affiliation>IFO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regina Elena National Cancer Institute</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regina Elena Cancer Institute</investigator_affiliation>
    <investigator_full_name>Paola Pinnaro</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>hypofractionated RT</keyword>
  <keyword>cosmetic outcome</keyword>
  <keyword>locoregional treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

